ENTPD1 and neoplasm: In the field of antitumor immunity, CD73 or CD39 inhibitors have emerged as novel therapeutic targets that exhibit superior anti-tumor activity, improve immunosuppressive microenvironment, and demonstrate synergistic effects in combination with chemotherapy and immunotherapy in preclinical studies.